Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
- 1-Propanone, 2-(eth
Ethylcathinone is a synthetic stimulant. It is similar to ecstasy in the sense that it provides euphoria, feelings of empathy and openness, and a desire to talk with others. It also carries over to some of the negative effects of ecstasy, such as insomnia, tightened jaw muscles, and grinding of the teeth.
It is structurally related to cathinone and methcathinone (MCAT), which broadly shares the effects profile of amphetamine or methylphenidate. Of the substituted cathinones, ETH-CAT reportedly produces the most moderate and residually long-lasting stimulation, with subtle effects that persist well after the initial rush. It has been described as having a more functional than recreational character due to the limited euphoria it produces for a stimulant, although its short active duration can promote compulsive redosing.
Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-CAT, and it has little history of human usage. It is primarily distributed as a research chemical on the online grey market. In 2008 it was identified as an ingredient in both quasi-legal “party pills”.
It has also been reported as having been sold as “ecstasy” along with another substituted cathinone, mephedrone. It is highly advised to use harm reduction practices if using this substance.
Substituted cathinones are all derivatives of cathinone, a stimulant substance which is structurally and functionally related to amphetamine and the principal active psychoactive component present in the khat plant (Catha edulis).
The cathinone molecule is comprised of a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group at the end of an ethyl side-chain that contains ketone group in the beta position. In distinction to its N-methylated lower homolog, methcathinone (M-CAT), ETH-CAT possesses an additional ethyl substitution at Rα.
ETH-CAT can be thought of as the cathinone analog of ethylamphetamine given it has the same general formula, differing only by the addition of a single double-bonded oxygen (i.e.
the ketone group).
|Avg. Mass||177.2429 Da|
|Monoisotopic Mass||177.115356 Da|
Interactions and Synergies
- Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
- Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
- The focus and anxiety caused by stimulants is magnified by psychedelics and results in an increased risk of thought loops
- The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
- No unexpected interactions, though likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
- Risk of tachycardia, hypertension, and manic states
- This combination of stimulants will increase strain on the heart. It is not generally worth it as cocaine has a mild blocking effect on dopamine releasers like amphetamine
- This combination of stimulants is not generally necessary and may increase strain on the heart, as well as potentially causing anxiety and greater physical discomfort.
- Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less. Extended release formulations may severely impede sleep, further worsening the hangover.
- Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
- Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
- The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
- Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and in extreme cases heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
- Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences. In extreme cases, they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
- The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- Both substances raise heart rate, in extreme cases, panic attacks caused by these drugs have led to more serious heart issues.
- This combination can easily lead to hypermanic states
- Both can dull each other's effects, so if one wears off before the other it's possible to overdose due to the lack of counteraction
|Marguis Test Result|
Although the effects of ETH-CAT have not been formally studied on the same level as traditional amphetamines or other substituted cathinones like methcathinone, it is possible to speculate that like other simple substituted cathinone, it most likely acts principally as a dopamine and norepinephrine reuptake inhibitor. The result of this is an effective increase in the levels of catecholamine neurotransmitters like dopamine and norepinephrine in the brain by binding to and partially blocking the transporter proteins that normally clear these neurotransmitters from the synaptic cleft. This enables dopamine and norepinephrine to accumulate between the synaptic clefts of key regions of the brain associated with reward, motivation, satisfaction and pleasure to extra-endogenous levels. This mechanism is thought to account for the stimulating, motivation enhancing and euphoric effects that this substance produces.
At low to moderate doses, ETH-CAT has been reported as being a relatively functional and effective amphetamine-like stimulant for performing general productivity tasks. It has a noticeably short duration of activity combined with a tendency to produce long-lasting residual stimulation well after the main effects have worn off, which can promote patterns of compulsive redosing in order to maintain a steady level of the desired amount of physical and cognitive stimulation.
- Physical euphoria
- Appetite suppression
- Increased heart rate
- Teeth grinding - This component can be considered to be less intense when compared with that of MDMA.
The cognitive effects of ETH-CAT can be broken down into several components which intensify proportional to dosage. The general head space of ETH-CAT is described by many as one of mental stimulation, focus enhancement and thought acceleration coupled with a mild sense of euphoria that is less pronounced than the head space of amphetamine, even at strong to heavy doses.
- Analysis enhancement
- Focus enhancement
- Motivation enhancement
- Anxiety - This compound produces little to no anxiety unless it is taken in large doses or redosed repeatedly.
- Thought acceleration
- Thought organization
- Cognitive euphoria - The cognitive euphoria that this substance produces is often reported to be extremely mild compared to other stimulants in its class.
- Compulsive redosing
- Visual haze
- Peripheral information misinterpretation - As with most other stimulants, this component primarily occurs at higher doses or after a sustained period of redosing.
ETH-CAT is currently a grey area compound within many parts of the world. People may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
- Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/15639609
- Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/20074881
- Police warn of potentially fatal 'fake ecstasy' | http://www.abc.net.au/news/2008-06-17/police-warn-of-potentially-fatal-fake-ecstasy/2475270
- Kelly, J. P. (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis, 3(7‐8), 439-453. https://doi.org/10.1002/dta.31
- Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database of Systematic Reviews, 1. https://doi.org/10.1002/14651858.CD003026.pub3
- Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects. Oxford University Press. ISBN 9780195030570.
- Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
- Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
- New blanket ban on synthetic illegal drugs is approved (Portuguese) | http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/combate-a-drogas-ilicitas-sinteticas-fica-mais-facil
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- Forbud mod tre nye stoffer | http://nyheder.tv2.dk/article.php/id-19197033.html?forside=
- "Anlage II BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
- "Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 25, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
- United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made
- ABI Chemicals AC1Q31EQ
- AKos AKOS022329753
- Ark Pharm, Inc. AK316968
- Aurora Fine Chemicals A02.326.349
- Aurora Fine Chemicals K11.756.681
- BindingDB 50023181
- ChEMBL CHEMBL3298876
- ChemDB 6683972
- ChemIDplus 18259375
- DiscoveryGate 458519
- eMolecules 497035
- Erowid Ethcathinone
- FDA UNII - NLM HV3BCK77BB
- Guide to PHARMACOLOGY 7398
- LabNetwork LN00223701
- Mcule MCULE-6743551229
- MuseChem M087840
- NIST Spectra mainlib_298693
- NIST Spectra mainlib_379093
- PubChem 458519
- Springer Nature Spectroscopic characterization and crystal structures of two cathinone derivatives: N-ethyl-2-amino-1-phenylpropan-1-one (ethcathinone) hydrochloride and N-ethyl-2-amino-1-(4-chlorophenyl)propan-1-one (4-CEC) hydrochloride
- Thomson Pharma 00513402
- VulcanChem VC213255
- Wikidata Q5403044
- Wikipedia Ethcathinone
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.